Skip to main content
. Author manuscript; available in PMC: 2012 Jun 15.
Published in final edited form as: Mutat Res. 2011 Jul 23;730(1-2):90–97. doi: 10.1016/j.mrfmmm.2011.07.006

Fig. 2.

Fig. 2

Comparisons of chemotherapy alone to combining chemotherapy with a telomerase inhibitor. Due to some toxicities in combining therapies in phase I clinical trials, a phase II trial is in progress using the telomerase inhibitor, Imetelstat, in a maintenance setting following standard chemotherapy.